- Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
- DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US
East Hanover, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis’ top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis. It has been studied clinically for more than 17 years and has been used to treat more than 1.8 million patients globally since its launch in 2015.
“Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients. We have long recognized that we need new ways to reach patients more directly by removing barriers in the system,” said Victor Bultó, President, US for Novartis. “The launch of this new platform is a first step as we continue to work toward solutions to provide our net prices more directly to patients and make the healthcare system work better for Americans.”
Through the DTP platform, Novartis will offer Cosentyx to American patients at a price that reflects the average savings that insurers and pharmacy benefit managers receive. The Cosentyx DTP platform serves as proof-of-concept for a direct-selling model for specialty medicines and ideally would work alongside insurance to help improve patient affordability. In the US, the company intends to offer a DTP option for additional medicines in its portfolio as appropriate and is exploring a direct-to-business model, selling Cosentyx, and potentially additional medicines, to large employers as another way to increase access and affordability.
Patient Assistance
Novartis offers multiple programs to help patients access Cosentyx, with the new DTP platform presenting an additional option. For US Cosentyx patients with commercial insurance, Novartis currently offers a program through which eligible patients may pay as little as $0 for their prescription. Through another support program, patients can receive help to investigate their insurance coverage and financial assistance to address out-of-pocket costs if they are commercially insured and otherwise eligible. Novartis also offers a program that can provide Cosentyx at no cost for up to two years if the patient is commercially insured and is in the process of appealing an initial denial of coverage.
Additionally, the Novartis Patient Assistance Foundation, Inc. (NPAF), an independent, 501(c)(3) non-profit entity, provides Cosentyx at no cost to eligible patients who cannot afford the cost of their Novartis medication, are uninsured or have government insurance, and meet income guidelines and other eligibility criteria.
In the US, COSENTYX® (secukinumab) is FDA-approved and a prescription medicine used to treat:
- people 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)
- people 2 years of age and older with active psoriatic arthritis (PsA)
- adults with active ankylosing spondylitis (AS)
- adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation
- people 4 years of age and older with active enthesitis-related arthritis (ERA)
- adults with moderate to severe hidradenitis suppurativa (HS)
IMPORTANT SAFETY INFORMATION
Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.
What is the most important information I should know about COSENTYX?
COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:
Infections
COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections while taking COSENTYX, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses. Some people have died from these infections.
- Your doctor should check you for TB before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not use COSENTYX if you have an active TB infection.
Before starting COSENTYX, tell your doctor if you:
- are being treated for an infection
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- think you have an infection or have symptoms of an infection such as:
|
|
- think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal
After starting COSENTYX, call your doctor right away if you have any signs of infection listed. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.
What are the possible side effects of COSENTYX?
COSENTYX may cause serious side effects, including:
Serious allergic reactions
Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; skin rash or hives (red, itchy bumps).
If you have a severe allergic reaction, do not give another injection of COSENTYX.
Inflammatory bowel disease
New cases of inflammatory bowel disease or “flare-ups” can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn’s disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.
Severe skin reactions that look like eczema can happen during treatment with COSENTYX from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with COSENTYX if you develop severe skin reactions. Tell your doctor if you have any of the following signs or symptoms: redness or rash; itching; small bumps or patches; your skin is dry or feels like leather; blisters on the hands or feet that ooze or become crusty or skin peeling.
The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory tract infections.
These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.
Before using COSENTYX, tell your doctor if you:
- have any of the conditions or symptoms listed for infections.
- have inflammatory bowel disease (Crohn’s disease or ulcerative colitis).
- are allergic to latex. The needle cap on the COSENTYX Sensoready® pen, and 150 mg/mL and 75 mg/0.5 mL prefilled syringes contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who take COSENTYX should not receive live vaccines. Children should be brought up to date with all vaccines before starting COSENTYX.
- have any other medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.
- are pregnant or plan to become pregnant. It is not known if COSENTYX can harm your unborn baby. You and your doctor should decide if you will use COSENTYX.
- are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes into your breast milk.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Prescribing Information, including Medication Guide.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram.
Novartis Media Relations
E-mail: [email protected]
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]